Biotechs Sepracor and Neurocrine Biosciences have seen shares soar as investors have seen potential for their entrants.
Wall Street expects that neither Sepracor's Estorra nor Neurocrine's indiplon will have any limits on how long they can be taken.
Meanwhile, regulars recently demanded more data before approving Neurocrine Biosciences ' indiplon sleeping pill, prompting partner Pfizer to drop its deal with Neurocrine last week.
Other companies, such as Neurogen, Aventis and Neurocrine Biosciences, are in early tests of drugs that block a damaging stress hormone often elevated in depressed patients.
Arena was founded in San Diego by Lief, a veteran drug executive with experience at Abbott and Cephalon, and researchers Dominic Behan and Derek Chalmers, who had both left San Diego biotech Neurocrine Biosciences to pursue novel ideas about drug development.
Meanwhile, regulars recently demanded more data before approving Neurocrine Biosciences ' (nasdaq: NBIX - news - people ) indiplon sleeping pill, prompting partner Pfizer (nyse: PFE - news - people ) to drop its deal with Neurocrine last week.
In December, Sepracor's Lunesta became the first sleeping pill approved without a restriction, limiting its use for a week or so, on its label. (Ambien has such a limitation, though many doctors prescribe it for longer.) Indiplon, being developed by Neurocrine and Pfizer, is likely to get similar labeling.
San Diego-based Neurocrine Biosciences (nasdaq: NBIX - news - people ) has teamed with Pfizer (nyse: PFE - news - people ) to sell Neurocrine's indiplon, which will be submitted to the FDA in the fourth quarter and could be available before the end of 2005.
In December, Sepracor's Lunesta became the first sleeping pill approved without a restriction, limiting its use for a week or so, on its label. (Ambien has such a limitation, though many doctors prescribe it for longer.) Indiplon, being developed by Neurocrine and Pfizer (nyse: PFE - news - people ), is likely to get similar labeling.
Arena was founded in San Diego by Lief, a veteran drug executive with experience at Abbott and Cephalon (nasdaq: CEPH - news - people ), and researchers Dominic Behan and Derek Chalmers, who had both left San Diego biotech Neurocrine Biosciences (nasdaq: NBIX - news - people ) to pursue novel ideas about drug development.
应用推荐